222 related articles for article (PubMed ID: 32361816)
21. Aggressive pituitary tumors in the young and elderly.
Tatsi C; Stratakis CA
Rev Endocr Metab Disord; 2020 Jun; 21(2):213-223. PubMed ID: 31912365
[TBL] [Abstract][Full Text] [Related]
22. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.
Thapar K; Scheithauer BW; Kovacs K; Pernicone PJ; Laws ER
Neurosurgery; 1996 Apr; 38(4):765-70; discussion 770-1. PubMed ID: 8692397
[TBL] [Abstract][Full Text] [Related]
23. Aggressive pituitary tumors.
Blevins LS; Verity DK; Allen G
Oncology (Williston Park); 1998 Sep; 12(9):1307-12, 1315; discussion 1315-8. PubMed ID: 9778677
[TBL] [Abstract][Full Text] [Related]
24. Pathobiology of pituitary adenomas and carcinomas.
Scheithauer BW; Gaffey TA; Lloyd RV; Sebo TJ; Kovacs KT; Horvath E; Yapicier O; Young WF; Meyer FB; Kuroki T; Riehle DL; Laws ER
Neurosurgery; 2006 Aug; 59(2):341-53; discussion 341-53. PubMed ID: 16883174
[TBL] [Abstract][Full Text] [Related]
25. Non-functioning pituitary adenomas: growth and aggressiveness.
Øystese KA; Evang JA; Bollerslev J
Endocrine; 2016 Jul; 53(1):28-34. PubMed ID: 27066792
[TBL] [Abstract][Full Text] [Related]
26. Pituitary tumours: pituitary incidentalomas.
Molitch ME
Best Pract Res Clin Endocrinol Metab; 2009 Oct; 23(5):667-75. PubMed ID: 19945030
[TBL] [Abstract][Full Text] [Related]
27. Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review.
de Aguiar PH; Aires R; Laws ER; Isolan GR; Logullo A; Patil C; Katznelson L
Neurol Res; 2010 Dec; 32(10):1060-71. PubMed ID: 20483025
[TBL] [Abstract][Full Text] [Related]
28. Atypical pituitary adenoma: a clinicopathologic case series.
Rutkowski MJ; Alward RM; Chen R; Wagner J; Jahangiri A; Southwell DG; Kunwar S; Blevins L; Lee H; Aghi MK
J Neurosurg; 2018 Apr; 128(4):1058-1065. PubMed ID: 28598278
[TBL] [Abstract][Full Text] [Related]
29. Epidemiology of Functioning Pituitary Adenomas.
Chin SO
Endocrinol Metab (Seoul); 2020 Jun; 35(2):237-242. PubMed ID: 32615708
[TBL] [Abstract][Full Text] [Related]
30. Treatment of pituitary carcinomas and atypical pituitary adenomas: a review.
Hirohata T; Ishii Y; Matsuno A
Neurol Med Chir (Tokyo); 2014; 54(12):966-73. PubMed ID: 25446382
[TBL] [Abstract][Full Text] [Related]
31. Pituitary adenomas in patients with multiple endocrine neoplasia type 1: a single-center experience in China.
Wu Y; Gao L; Guo X; Wang Z; Lian W; Deng K; Lu L; Xing B; Zhu H
Pituitary; 2019 Apr; 22(2):113-123. PubMed ID: 30637623
[TBL] [Abstract][Full Text] [Related]
32. Atypical pituitary adenomas: 10 years of experience in a reference centre in Portugal.
Tortosa F; Webb SM
Neurologia; 2016 Mar; 31(2):97-105. PubMed ID: 26300499
[TBL] [Abstract][Full Text] [Related]
33. Refractory pituitary adenoma: a novel classification for pituitary tumors.
Dai C; Feng M; Liu X; Ma S; Sun B; Bao X; Yao Y; Deng K; Wang Y; Xing B; Lian W; Zhong D; Ma W; Wang R
Oncotarget; 2016 Dec; 7(50):83657-83668. PubMed ID: 27845901
[TBL] [Abstract][Full Text] [Related]
34. Targeted systemic and peptide radio-ligand therapy for aggressive pituitary tumors and carcinomas.
Petersenn S; Heaney AP
Rev Endocr Metab Disord; 2020 Jun; 21(2):277-286. PubMed ID: 32415583
[TBL] [Abstract][Full Text] [Related]
35. Invasive, atypical and aggressive pituitary adenomas and carcinomas.
Sav A; Rotondo F; Syro LV; Di Ieva A; Cusimano MD; Kovacs K
Endocrinol Metab Clin North Am; 2015 Mar; 44(1):99-104. PubMed ID: 25732646
[TBL] [Abstract][Full Text] [Related]
36. Asymptomatic large pituitary adenomas discovered at autopsy.
Auer RN; Alakija P; Sutherland GR
Surg Neurol; 1996 Jul; 46(1):28-31. PubMed ID: 8677484
[TBL] [Abstract][Full Text] [Related]
37. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium.
Daly AF; Rixhon M; Adam C; Dempegioti A; Tichomirowa MA; Beckers A
J Clin Endocrinol Metab; 2006 Dec; 91(12):4769-75. PubMed ID: 16968795
[TBL] [Abstract][Full Text] [Related]
38. Argyrophilic nucleolar organizer region proteins (AgNORs) as an index of clinical and radiological invasiveness in pituitary adenomas.
Uma B; Chacko G; Chandy MJ
Br J Neurosurg; 1998 Dec; 12(6):582-4. PubMed ID: 10070473
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of corticotroph staining in radiosurgery for non-functioning pituitary adenomas: a multicenter study.
Cohen-Inbar O; Xu Z; Lee CC; Wu CC; Chytka T; Silva D; Sharma M; Radwan H; Grills IS; Nguyen B; Siddiqui Z; Mathieu D; Iorio-Morin C; Wolf A; Cifarelli CP; Cifarelli DT; Lunsford LD; Kondziolka D; Sheehan JP
J Neurooncol; 2017 Oct; 135(1):67-74. PubMed ID: 28913674
[TBL] [Abstract][Full Text] [Related]
40. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery.
Meij BP; Lopes MB; Ellegala DB; Alden TD; Laws ER
J Neurosurg; 2002 Feb; 96(2):195-208. PubMed ID: 11838791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
